Gilead Sciences Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2008 | $2.14B | $2.03B | $115.0M | $153.4M |
| FY2009 | $3.08B | $2.85B | $230.1M | $180.7M |
| FY2010 | $2.83B | $2.77B | $61.9M | $200.0M |
| FY2011 | $3.64B | $3.51B | $131.9M | $192.4M |
| FY2012 | $3.20B | $2.80B | $397.0M | $209.0M |
| FY2013 | $3.11B | $2.97B | $134.0M | $252.0M |
| FY2014 | $12.82B | $12.26B | $557.0M | $360.0M |
| FY2015 | $21.25B | $20.50B | $747.0M | $382.0M |
| FY2016 | $17.05B | $16.30B | $748.0M | $380.0M |
| FY2017 | $11.90B | $11.31B | $590.0M | $638.0M |
| FY2018 | $8.40B | $7.48B | $924.0M | $845.0M |
| FY2019 | $9.14B | $8.32B | $825.0M | $636.0M |
| FY2020 | $8.17B | $7.52B | $650.0M | $643.0M |
| FY2021 | $11.38B | $10.81B | $579.0M | $635.0M |
| FY2022 | $9.07B | $8.34B | $728.0M | $637.0M |
| FY2023 | $8.01B | $7.42B | $585.0M | $766.0M |
| FY2024 | $10.83B | $10.31B | $523.0M | $835.0M |
| FY2025 | $10.02B | $9.46B | $563.0M | $894.0M |